Fig. 1

Modulation of activated SCD-1 and CD36 by PI3K inhibitors in HER2-positive breast cancer cells. (a) The basal protein levels of SCD-1 and CD36 were assessed by western blotting in MDA-MB-231 (HER2-negative), SK-BR-3 (HER2-positive), and HCC1569 (HER2-positive/PTEN-loss) breast cancer cells. Pre: precursor; Mat, mature. (b) The effects of PI3K inhibitors alpelisib (upper panel) and inavolisib (bottom panel) on the proliferation of SK-BR-3 and HCC1569 cells. The cell numbers were assessed by the WST-1 assay and the results are presented as a percentage of the untreated control (mean ± SEM). (c, d) The modulated protein levels of SCD-1 and CD36 were assessed by western blotting in SK-BR-3 and HCC1569 cells treated with PI3K inhibitors for 24 h. The protein expression is expressed relative to the untreated control (mean ± SEM), **P < 0.01 and ***P < 0.001